Date: 2011-10-17
Type of information: Series A financing round
Company: Hoopika Biotech (Austria)
Investors: Sofinnova Partners (France) Forbion Capital Partners (The Netherlands)
Amount: €7 million
Funding type: series A financing round
Planned used: Hookipa Biotech is a biotech startup company founded in July 2011 in Austria. The company utilizes its proprietary Vaxwave™ technology platform to develop genetic vaccines for the prophylactic and therapeutic treatment of diseases. Vaxwave™ introduces a new approach to vaccination by providing long lasting and potent stimulation of both cellular and humoral immunity; the platform has been validated in different disease models. The company will use the Series A funds to advance its lead product HB101 through pre-clinical development and a Phase I proof of concept study, and to further industrialize and validate the Vaxwave™ technology.
Others: * On October 17, 2011, Hookipa Biotech, a startup biotech company specialized in developing new generation vaccines, announced that it has raised €7 million Series A financing led by Sofinnova Partners. Forbion Capital Partners joined the syndicate as the co-investor.
Therapeutic area: Cancer - Oncology - Infectious diseases